本文へ移動
cccskills
無料GitHub で公開

mapi-score-calculator

Calculate the Maryland Aggregate Pathology Index (MAPI) on a deceased donor procurement kidney biopsy to predict graft survival and decide single vs dual vs discard allocation. Trigger when a clinician asks "what's the MAPI score", "interpret donor kidney biopsy", "should I use this marginal kidney", "MAPI cutoff for transplant", "procurement biopsy scoring", or has histology results from a deceased donor kidney and needs an objective grading.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md4.9 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

MAPI Score Calculator — Deceased Donor Kidney Biopsy

Use this skill when a procurement biopsy has been performed on a deceased donor kidney (typically a marginal/ECD donor) and an objective histological grading is needed to decide:

  • Single kidney transplant (low risk)
  • Dual kidney transplant (intermediate risk)
  • Discard (high risk)

The Maryland Aggregate Pathology Index (MAPI) is the scoring system recommended by ISOT 2025 for marginal deceased donor kidney evaluation.


STEP 1 — Ensure biopsy adequacy

A reliable MAPI requires:

  • Wedge biopsy (preferred) or needle core biopsy with adequate cortex.
  • ≥25 glomeruli for valid glomerulosclerosis assessment.
  • At least one artery for arteriolar scoring.
  • Both kidneys assessed if dual transplant is being considered.

If the biopsy is inadequate → repeat or proceed on clinical grounds alone.


STEP 2 — Score the four histological components

ComponentFindingPoints
Glomerulosclerosis<15%0
15–20%4
>20%7
Tubular atrophyAbsent0
<50% of cortex affected1
≥50% of cortex affected3
Interstitial fibrosisAbsent0
Mild (Banff ci1, 6–25%)2
Moderate–severe (Banff ci2/ci3, >25%)5
Arteriolar narrowing / hyalinosisAbsent0
Wall thickening less than the diameter of the lumen2
Wall thickening greater than the diameter of the lumen4

MAPI total = sum of all four components (range 0–19).


STEP 3 — Interpret the score

MAPIRisk bandApproximate 5-yr graft survivalAction
<7Low~90%✅ Use as single kidney transplant
7–11Intermediate~70–80%⚠️ Dual kidney transplant (en bloc or paired single) — OR allocate single only to lower-immunological-risk recipient
>11High<70%❌ Discard, or dual transplant only if recipient has no alternative

STEP 4 — Combine with clinical context

Histology is one input — combine with:

  • Donor age (>70 raises threshold for single use)
  • KDRI / KDPI if available
  • Cold ischaemia time
  • Recipient sensitisation, age, and waiting time
  • Macroscopic appearance of kidney (vasculature, parenchyma)

ISOT 2025 guidance: if procurement biopsy is not feasible, base the decision on clinical severity, degree of oliguria, and need for dialysis in the donor.


STEP 5 — Document the decision

Output should include the MAPI score, the four component scores, the risk band, and the allocation decision.


CLINICAL GUARDRAILS

  • MAPI is for marginal/ECD donors — not needed for standard criteria donors.
  • The score is one tool, not the entire decision — a MAPI of 8 in a 35-year-old donor with brief CIT is very different from MAPI 8 in a 72-year-old after 20 hours of CIT.
  • Glomerulosclerosis dominates the score — if >20% globally sclerosed glomeruli, the score is already ≥7 regardless of other components.
  • Dual kidney transplant adds technical complexity and anastomosis time — weigh this against the expected graft survival benefit.
  • A single reading is operator-dependent — where possible, get a transplant pathologist (not a general pathologist on call) to score.
  • AKI changes the picture — see the AKI donor decision skill; tubular injury from AKI can over-inflate the tubular atrophy score on frozen section.

OUTPUT TEMPLATE

DONOR: [age, sex, comorbidities, cause of death, CIT]
BIOPSY: [type, glomerulus count, adequacy]

Glomerulosclerosis: __% → __ points
Tubular atrophy: __ → __ points
Interstitial fibrosis: __ → __ points
Arteriolar narrowing: __ → __ points

MAPI total: __ / 19
Risk band: [Low / Intermediate / High]

Decision: [Single KT / Dual KT / Discard]
Justification: [combine MAPI + clinical context]

SOURCE

Munivenkatappa RB, Schweitzer EJ, Papadimitriou JC, et al. The Maryland aggregate pathology index: a deceased donor kidney biopsy scoring system for predicting graft failure. American Journal of Transplantation 2008;8(11):2316–2324. DOI: 10.1111/j.1600-6143.2008.02370.x

Referenced in: Balwani MR, Kute VB, Shrimali J, et al. ISOT position statement on the feasibility of an organ for transplantation from brain-dead deceased donors: a Delphi consensus. The Lancet Regional Health – Southeast Asia 2025;39:100628 (Supplementary Table S4, marginal donor kidney evaluation).

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する